Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Atea Pharmaceuticals, Inc. (AVIR)

7.13   0.19 (2.74%) 06-26 22:05
Open: 6.97 Pre. Close: 6.94
High: 7.42 Low: 6.93
Volume: 1,991,076 Market Cap: 594(M)
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.42 - 7.45 7.45 - 7.47
Low: 6.86 - 6.89 6.89 - 6.92
Close: 7.08 - 7.12 7.12 - 7.17

Technical analysis

as of: 2022-06-24 4:38:12 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 8.7     One year: 9.68
Support: Support1: 6.09    Support2: 5.06
Resistance: Resistance1: 7.45    Resistance2: 8.29
Pivot: 7.11
Moving Average: MA(5): 6.81     MA(20): 7.29
MA(100): 6.69     MA(250): 14.35
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 40.6     %D(3): 33.7
RSI: RSI(14): 51.3
52-week: High: 46.9  Low: 5.3
Average Vol(K): 3-Month: 757 (K)  10-Days: 1,112 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AVIR ] has closed below upper band by 49.4%. Bollinger Bands are 56.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Headline News

Sun, 26 Jun 2022
Wireless Sensorsfor Environmental and Agricultural Monitoring Market Outlook 2022 And Growth By Top KeyPlayers – American Sensor, ASM Automation, Automata, Avir Sensors – Designer Women - Designer Women

Tue, 21 Jun 2022
Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference - GuruFocus.com

Thu, 16 Jun 2022
Agricultural Wireless Sensors Market Outlook 2022 And Forecast to 2029 | Key Players – ESI ENVIRONMENTAL SENSORS INC., AVIR SENSORS, ASM AUTOMATION SENSORIK MESSTECHNIK GMBH, AUTOMATA INC. – Designer Women - Designer Women

Sun, 12 Jun 2022
Atea Pharmaceuticals (NASDAQ:AVIR) shareholders have endured a 68% loss from investing in the stock a year ago - Yahoo Movies UK

Thu, 09 Jun 2022
Insiders who purchased Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) stock last year recover some losses which currently stand at US$6.1k - Simply Wall St

Sun, 05 Jun 2022
-$0.49 EPS Expected for Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) This Quarter - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 83 (M)
Shares Float 69 (M)
% Held by Insiders 10.5 (%)
% Held by Institutions 71.2 (%)
Shares Short 1,960 (K)
Shares Short P.Month 2,090 (K)

Stock Financials

EPS 0.31
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7
Profit Margin (%) 34.4
Operating Margin (%) 39.3
Return on Assets (ttm) 10.5
Return on Equity (ttm) 19.2
Qtrly Rev. Growth 295.2
Gross Profit (p.s.) 2.21
Sales Per Share 4.22
EBITDA (p.s.) 1.66
Qtrly Earnings Growth 264.1
Operating Cash Flow -87 (M)
Levered Free Cash Flow -128 (M)

Stock Valuations

PE Ratio 23
PEG Ratio 0
Price to Book value 1.01
Price to Sales 1.68
Price to Cash Flow -6.82

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.